Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study
About This Trial
- This study looks at how a targeted radiation therapy called lutetium vipivotide tetraxetan affects patients' daily quality of life in regular medical practice.
- It is designed for adults with advanced prostate cancer that has spread and no longer responds to hormone treatments, who are already scheduled to receive this medication from their doctor.
- Because this is an observational study, you will receive standard care while answering questions about your well-being before, during, and for up to one year after treatment.
- To take part, you cannot be enrolled in any other experimental clinical trials at the same time.
More Information
- The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Who Can Enroll
- Age Range: 18 - 99 years
- Gender: Male
- Who This Trial is For: This study looks at how a targeted radiation therapy called lutetium vipivotide tetraxetan affects patients' daily quality of life in regular medical practice.
Study Details
- Start Date: September 4, 2024
- Lead Sponsor: Novartis Pharmaceuticals
Full Eligibility Criteria
Inclusion Criteria
All patients must meet the following inclusion criteria during the identification period:
- Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
- ≥ 18 years old at the time of enrollment
- Written informed consent must be obtained prior to any data collection
- Willing to participate in Quality of Life post treatment date collection for 1 year
Exclusion Criteria
Patients must not meet the following exclusion criterion during the identification
period:
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan
Treatments
- Other: lutetium (177Lu) vipivotide tetraxetan